Eyenovia to end eye drug study, cut 50% of its workforce
Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.
Related Articles
Early COVID-19 Infections Linked With Higher Heart Attack, Stroke Risk
People who contracted COVID-19 during the early stages of the pandemic had an increased risk of myocardial infarction (heart attack), stroke, and death for the…
What Is Deep Brain Stimulation?
This surgical procedure is considered when medication is no longer adequate in maintaining the quality of life for patients struggling with neurological conditions.
The rising tide of maritime cyberthreats in global trade
The ongoing threat of cyber attacks in maritime global trade
Finding Community When You Have HER2-Low Metastatic Breast Cancer
A palliative medicine specialist explains how to put HER2-low metastatic breast cancer resources to use.
DEA, HHS to extend remote prescribing for another year
This is the third extension of COVID-19 era remote prescribing flexibilities.
Russell body typhilitis: An unusual mimicker of malignancy!
Colorectal Russell body lesions are exceedingly rare with only four cases described in literature to date.1 We report here a case of Russell body typhilitis…
CDC confirms Oregon’s first human case of bird flu
The U.S. Centers for Disease Control and Prevention (CDC) on Friday confirmed highly pathogenic form of bird flu in a person in Oregon.
OpenAI’s new policy blueprint for AI imagines a role for government
The company wants help with energy, infrastructure and economic zones.
Gift Empowers Trainees To Leverage Clinical AI for Better Health
$6 million in funding equips scientists, leaders of the future
What Attention-Seeking Behavior Looks Like and Why It Happens
A psychologist explains what attention-seeking behavior is, its many causes and how to stop it.